{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:26:52Z","timestamp":1765546012859,"version":"3.40.5"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["BBA Clinical"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbacli.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T04:59:35Z","timestamp":1434171575000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Treatment of non-muscle invasive bladder cancer with Bacillus Calmette\u2013Guerin (BCG): Biological markers and simulation studies"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-9778","authenticated-orcid":false,"given":"Alex","family":"Kiselyov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Bunimovich-Mendrazitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Startsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbacli.2015.06.002_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0010","series-title":"Smith's General Urology","first-page":"308","article-title":"Urothelial carcinoma: cancers of the bladder, ureter, & renal pelvis","author":"Konety","year":"2008"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1464-410X.2005.05928.x","article-title":"The management of superficial transitional cell carcinoma of the bladder: a critical assessment of contemporary concepts and future perspectives","volume":"96","author":"Vogeli","year":"2005","journal-title":"BJU Int."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.urolonc.2005.07.005","article-title":"Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder","volume":"24","author":"Soloway","year":"2006","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0025","series-title":"Immunotherapy of Urinary Bladder Carcinoma: BCG and Beyond","first-page":"319","author":"Luo","year":"2013"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0030","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with Bacillus Calmette\u2013Gu\u00e9rin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0050","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette\u2013Guerin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0055","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1517\/17460441.2014.941351","article-title":"Mathematical modeling for novel cancer drug discovery and development","volume":"9","author":"Zhang","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0060","doi-asserted-by":"crossref","first-page":"e1003231","DOI":"10.1371\/journal.pcbi.1003231","article-title":"Predictive modeling of in vivo response to gemcitabine in pancreatic cancer","volume":"9","author":"Lee","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0065","doi-asserted-by":"crossref","first-page":"e1003008","DOI":"10.1371\/journal.pcbi.1003008","article-title":"An integrated computational\/experimental model of lymphoma growth","volume":"9","author":"Frieboes","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0070","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","article-title":"Internalization of bacille Calmette\u2013Guerin by bladder tumor cells","volume":"145","author":"Becich","year":"1991","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette\u2013Guerin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"De Reijke","year":"1996","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0080","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer-the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"De Boer","year":"1991","journal-title":"Urol. Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette\u2013Gu\u00e9rin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2249.2006.03288.x","article-title":"Mycobacterium bovis bacillus Calmette\u2013Gu\u00e9rin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo","volume":"147","author":"Luo","year":"2007","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1462-5822.2004.00489.x","article-title":"Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation","volume":"7","author":"Godaly","year":"2005","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0105","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette\u2013Guerin-induced antitumor activity","volume":"64","author":"Ludwig","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette\u2013Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"B\u00f6hle","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0115","doi-asserted-by":"crossref","first-page":"e69892","DOI":"10.1371\/journal.pone.0069892","article-title":"Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with BC and show similar cytokine profiles as in active tuberculosis","volume":"8","author":"Elsaesser","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0120","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","article-title":"Mechanisms of bacillus Calmette\u2013Guerin mediated natural killer cell activation","volume":"172","author":"Suttmann","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0125","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette\u2013Gu\u00e9rin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to Bacillus Calmette\u2013Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","author":"Zuiverloon","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0140","doi-asserted-by":"crossref","first-page":"23,897","DOI":"10.3390\/ijms151223897","article-title":"The promise of novel molecular markers in bladder cancer","volume":"15","author":"Miremami","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0145","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0150","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s13277-013-1547-8","article-title":"Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG","volume":"35","author":"Zachos","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0155","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.eururo.2014.05.033","article-title":"The effect of age on the efficacy of maintenance Bacillus Calmette\u2013Gu\u00e9rin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC Genito-Urinary Group Study 30911","volume":"66","author":"Oddens","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0160","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette\u2013Guerin","volume":"56","author":"Palou","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0165","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5347(01)61770-1","article-title":"Correlation and prognostic significance of p53, p21WAF1\/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette\u2013Gu\u00e9rin intravesical therapy","volume":"161","author":"Zlotta","year":"1999","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","article-title":"Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer","volume":"65","author":"Bertz","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0175","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.juro.2008.11.090","article-title":"Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette\u2013Guerin instillation","volume":"181","author":"Takayama","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0180","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bju.12641","article-title":"Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study","volume":"115","author":"Andrew","year":"2015","journal-title":"BJU Int."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0185","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1200\/JCO.2005.01.598","article-title":"Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival","volume":"23","author":"Leibovici","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.arcmed.2010.03.005","article-title":"IL-8 _251 T>A polymorphism is associated with bladder cancer susceptibility and outcome after BCG immunotherapy in a northern Indian cohort","volume":"41","author":"Ahirwar","year":"2010","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0195","doi-asserted-by":"crossref","first-page":"44.e1","DOI":"10.1016\/j.urolonc.2013.05.009","article-title":"FASL polymorphism is associated with response to bacillus Calmette\u2013Guerin immunotherapy in bladder cancer","volume":"32","author":"Lima","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0200","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to Bacillus Calmette\u2013Guerin therapy for bladder cancer","volume":"59","author":"Chiong","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0205","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4161\/cbt.7.5.5763","article-title":"XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy","volume":"7","author":"Mittal","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13547500902818246","article-title":"Cytokine gene polymorphisms are associated with risk of urinary BC and recurrence after BCG immunotherapy","volume":"14","author":"Ahirwar","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0215","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.27949","article-title":"microRNA expression profile in a large series of bladder tumors: Identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancers","volume":"132","author":"Pignot","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0220","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1586\/erm.12.114","article-title":"Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers","volume":"12","author":"Oliveira","year":"2012","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0225","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eururo.2012.11.030","article-title":"Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer","volume":"63","author":"Shimizu","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.juro.2013.01.105","article-title":"Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study","volume":"190","author":"Garcia-Baquero","year":"2013","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0235","first-page":"779","article-title":"Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study","volume":"33","author":"Hauser","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0240","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1038\/bjc.2013.571","article-title":"In vitro studies demonstrated higher adhesion and internalization of the bacillus to cells expressing sTn, promoting cell death","volume":"109","author":"Lima","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0245","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1038\/bjc.2013.215","article-title":"Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer","volume":"108","author":"Boman","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0250","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3892\/mmr.2013.1873","article-title":"Urine tenascin-C is an independent risk factor for bladder cancer patients","volume":"9","author":"Guan","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0255","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.25733","article-title":"Bacillus Calmette\u2013Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells","volume":"129","author":"Carretero","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0260","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0265","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette\u2013Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0270","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette\u2013Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0275","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3892\/etm.2012.634","article-title":"Prediction of response to bacillus Calmette\u2013Guerin treatment in non-muscle invasive bladder cancer patients through interleukin-6 and interleukin-10 ratio","volume":"4","author":"Tommaso","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0280","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2249.2010.04105.x","article-title":"Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette\u2013Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells","volume":"160","author":"Luo","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0285","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","article-title":"Interleukin-8 expression in the urine after bacillus Calmette\u2013Guerin therapy: a potential prognostic factor of tumor recurrence and progression","volume":"158","author":"Thalmann","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0290","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2490-12-12","article-title":"IL-8 as a urinary biomarker for the detection of bladder cancer","volume":"12","author":"Urquidi","year":"2012","journal-title":"BMC Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0295","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0022-5347(01)64111-9","article-title":"Urinary interleukin-8\/creatinine level as a predictor of response to intravesical bacillus Calmette\u2013Guerin therapy in bladder tumor patients","volume":"158","author":"Rabinowitz","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0300","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.3816\/CGC.2009.n.016","article-title":"Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette\u2013Guerin treatment in non-muscle invasive bladder tumors","volume":"7","author":"Sagnak","year":"2009","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0305","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/eji.201040773","article-title":"IL-17 production by \u03b3\u03b4 T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette\u2013Guerin treatment against bladder cancer","volume":"41","author":"Takeuchi","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0310","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0315","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jprot.2012.09.002","article-title":"Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis 2D-DIGE","volume":"77","author":"Li","year":"2012","journal-title":"J. Proteomics"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0320","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.urolonc.2011.06.004","article-title":"Do molecular biomarkers have prognostic value in primary T1G3 BC treated with bacillus Calmette\u2013Guerin intravesical therapy?","volume":"31","author":"Park","year":"2013","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0325","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU Int."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Esuvaranathan","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0335","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/cncr.24770","article-title":"Reactive antibodies against bacillus Calmette\u2013Guerin heat-shock protein-65 potentially predict the outcome of immunotherapy for high-grade transitional cell carcinoma of the bladder","volume":"116","author":"Ardelt","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0340","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s101470200024","article-title":"BCG effects on telomerase activity in bladder cancer cell lines","volume":"7","author":"Saitoh","year":"2002","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0345","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.niox.2012.07.001","article-title":"Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer","volume":"27","author":"Koskela","year":"2012","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0350","first-page":"25","article-title":"Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma","volume":"30","author":"Mansoor","year":"2008","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0355","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2490-12-23","article-title":"Influencing factors on the NMP-22 urine assay: an experimental model","volume":"12","author":"Miyake","year":"2012","journal-title":"BMC Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040305","article-title":"Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22","volume":"7","author":"Kelly","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0365","first-page":"2650","article-title":"HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker","volume":"133","author":"Lorenzi","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0370","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.urolonc.2010.08.018","article-title":"PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer","volume":"30","author":"Yun","year":"2012","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0375","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/mc.21978","article-title":"Expression of UDP-glucuronosyltransferase 1A in bladder cancer: Association with prognosis and regulation by estrogen","volume":"53","author":"Izumi","year":"2014","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0380","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/j.1476-5381.2012.02020.x","article-title":"Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing","volume":"167","author":"Mirams","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0385","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1158\/0008-5472.CAN-12-3588","article-title":"Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression","volume":"73","author":"Neal","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0390","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1158\/0008-5472.CAN-08-3740","article-title":"Prediction of drug response in breast cancer using integrative experimental\/computational modelling","volume":"69","author":"Frieboes","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0395","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1098\/rsif.2010.0194","article-title":"Predictions of tumour morphological stability and evaluation against experimental observations","volume":"8","author":"Pham","year":"2011","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.bbacli.2015.06.002_bb0400","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1158\/0008-5472.CAN-10-0701","article-title":"In silico modeling and in vivo efficacy of cancer-preventive vaccinations","volume":"70","author":"Palladini","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0405","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s11538-007-9195-z","article-title":"Mathematical model of BCG immunotherapy in superficial bladder cancer","volume":"69","author":"Bunimovich-Mendrazitsky","year":"2007","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0410","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s11538-008-9344-z","article-title":"Mathematical model of pulsed immunotherapy for superficial bladder cancer","volume":"70","author":"Bunimovich-Mendrazitsky","year":"2008","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtbi.2011.02.008","article-title":"A mathematical model of combined Bacillus Calmette\u2013Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer","volume":"277","author":"Bunimovich-Mendrazitsky","year":"2011","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0420","first-page":"1","article-title":"Improving Bacillus Calmette Guerin (BCG) immunotherapy for bladder cancer by adding interleukin-2 (IL-2): a mathematical model","author":"Bunimovich-Mendrazitsky","year":"2015","journal-title":"Math. Med. Biol."},{"issue":"3","key":"10.1016\/j.bbacli.2015.06.002_bb0425","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002850050127","article-title":"Modelling immunotherapy of the tumor-immune interaction","volume":"37","author":"Kirschner","year":"1998","journal-title":"J. Math. Biol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0430","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02460644","article-title":"Nonlinear dynamics of immunogenic tumours: parameter estimation and global bifurcation analysis","volume":"56","author":"Kuznetsov","year":"1994","journal-title":"Bull. Math. Biol."},{"issue":"17","key":"10.1016\/j.bbacli.2015.06.002_bb0435","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1158\/0008-5472.CAN-05-0564","article-title":"A validated mathematical model of cell-mediated immune response to tumor growth","volume":"65","author":"De Pillis","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0440","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance BCG immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.bbacli.2015.06.002_bb0445","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.drudis.2013.06.015","article-title":"Mathematical modeling in cancer drug discovery","volume":"19","author":"Wang","year":"2013","journal-title":"Drug Discov. Today"}],"container-title":["BBA Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647415000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214647415000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T18:04:40Z","timestamp":1566842680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214647415000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":89,"alternative-id":["S2214647415000719"],"URL":"https:\/\/doi.org\/10.1016\/j.bbacli.2015.06.002","relation":{},"ISSN":["2214-6474"],"issn-type":[{"type":"print","value":"2214-6474"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of non-muscle invasive bladder cancer with Bacillus Calmette\u2013Guerin (BCG): Biological markers and simulation studies","name":"articletitle","label":"Article Title"},{"value":"BBA Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbacli.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}